1. Home
  2. BGLC vs NEUP Comparison

BGLC vs NEUP Comparison

Compare BGLC & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • NEUP
  • Stock Information
  • Founded
  • BGLC 2017
  • NEUP 1996
  • Country
  • BGLC Malaysia
  • NEUP United States
  • Employees
  • BGLC N/A
  • NEUP N/A
  • Industry
  • BGLC Medical Specialities
  • NEUP
  • Sector
  • BGLC Health Care
  • NEUP
  • Exchange
  • BGLC Nasdaq
  • NEUP Nasdaq
  • Market Cap
  • BGLC 10.7M
  • NEUP 12.7M
  • IPO Year
  • BGLC N/A
  • NEUP N/A
  • Fundamental
  • Price
  • BGLC $5.09
  • NEUP $7.72
  • Analyst Decision
  • BGLC
  • NEUP Strong Buy
  • Analyst Count
  • BGLC 0
  • NEUP 1
  • Target Price
  • BGLC N/A
  • NEUP $21.00
  • AVG Volume (30 Days)
  • BGLC 2.7M
  • NEUP 30.4K
  • Earning Date
  • BGLC 08-13-2025
  • NEUP 08-15-2025
  • Dividend Yield
  • BGLC N/A
  • NEUP N/A
  • EPS Growth
  • BGLC N/A
  • NEUP N/A
  • EPS
  • BGLC N/A
  • NEUP 0.00
  • Revenue
  • BGLC $9,265,870.00
  • NEUP $15,662,715.00
  • Revenue This Year
  • BGLC N/A
  • NEUP N/A
  • Revenue Next Year
  • BGLC N/A
  • NEUP N/A
  • P/E Ratio
  • BGLC N/A
  • NEUP $4,532.08
  • Revenue Growth
  • BGLC N/A
  • NEUP N/A
  • 52 Week Low
  • BGLC $2.01
  • NEUP $2.90
  • 52 Week High
  • BGLC $15.60
  • NEUP $126.00
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 52.61
  • NEUP N/A
  • Support Level
  • BGLC $5.33
  • NEUP N/A
  • Resistance Level
  • BGLC $6.39
  • NEUP N/A
  • Average True Range (ATR)
  • BGLC 1.18
  • NEUP 0.00
  • MACD
  • BGLC 0.10
  • NEUP 0.00
  • Stochastic Oscillator
  • BGLC 19.15
  • NEUP 0.00

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Share on Social Networks: